Tactile Systems Technology (TCMD) delivered a quarter in which the core franchise improved and nearly everything around it got harder. Third-quarter earnings of $0.31 per share beat the $0.30 consensus by 3.3%. But revenue of $91.86 million missed the $92.84 million estimate by 1.1%, and earnings fell 13.9% year over year even as revenue grew 7.1%. The central tension is plain. Lymphedema, which now accounts for 89% of sales, accelerated to 13% growth. Airway clearance fell 25% as the AffloVest product transition dragged on, and operating expense growth absorbed all of the gross-margin gains.

The quality of the beat deserves scrutiny. A one-cent EPS beat that comes alongside a revenue miss and a year-over-year profit decline is not a demand-driven upside surprise.

• **Gross profit:** rose 8% to $70.5 million. Gross margin expanded for a 12th straight quarter to roughly 77%, helped by lower manufacturing costs and mix.
• **Operating expenses:** jumped 13% to $60.9 million, led by sales and marketing and reimbursement, general and administrative spending.
• **Operating income:** slipped to $9.6 million from $11.0 million.
• **Adjusted EBITDA:** flat at $14.3 million, with margin compressing to about 15.6% from 16.8%.
• **Cash flow:** nine-month operating cash flow of $14.9 million was well below the prior year's $25.5 million, reflecting working-capital swings. Third-quarter operating cash flow was a healthier $12 million and funded $6.2 million of buybacks.

Beneath the headline, the lymphedema story genuinely improved. Growth of 13% compares with 12% in the second quarter, and the business rose 11% sequentially, marking a fifth straight double-digit quarter. Management declared the Medicare prior-authorization disruption from earlier in the year behind it. Medicare lymphedema revenue grew 11% after declining in the second quarter, while commercial rose 17%. Productivity indicators also moved the right way: clinic visits rose 19%, referring clinics were up 10% year to date, and more than 13,000 clinicians have been educated so far this year.

Airway clearance is the opposite story, and the trajectory is what stings. Revenue in that line grew 22% in the first quarter, fell 7% in the second, and fell 25% in the third. The full-year outlook was cut again, now to a mid-to-high single-digit decline. That compares with roughly flat expectations in August and growth matching or beating lymphedema earlier in the year. Distributor (DME) inventory is burning down more slowly than expected. Management acknowledged limited real-time visibility into stock concentrated among a few large partners, which gives bears legitimate ammunition on forecasting credibility.

Management held 2026 revenue guidance at $360 million to $366 million. That range implies fourth-quarter revenue of roughly $107 million to $113 million. It also raised adjusted EBITDA guidance to $50 million to $52 million from $49 million to $51 million, and tightened gross margin to about 76.5%.

The pipeline gave the call a credible forward narrative:

• the FDA cleared the LymphaTech 3D scanner's expanded indication ahead of the 2027 timing flagged last quarter;
• the Flexitouch Pro 510(k) has been filed, with launch targeted for the second half of 2027;
• early commercial payers dropped the experimental designation for head-and-neck lymphedema;
• a MyoSleeve VA pilot starts late in the fourth quarter.

Offsetting that, management warned that fourth-quarter lymphedema growth will moderate against a 16% comparison. It also explicitly tempered 2027 expectations, saying there will be "no hockey stick," with operational investment continuing into 2028.

Investors were not leaning bullish going in. Earnings Whispers sentiment remained negative and weakened modestly, slipping from -0.18 to -0.28. Shares entered the report at $23.04, essentially unchanged (-1.2%) from the open after the August report. They sat 11% below the 200-day moving average and about 9% below the inter-earnings high of $25.32, which was set the day after the last release. The stock has since rebounded about 8% off its September low. The trend readings are mixed: sequential growth is positive, while price and AVWAP trends remain negative. That mix fits a market crediting the lymphedema recovery but unwilling to pay up while airway clearance keeps resetting lower.

The bottom line is that Tactile's core lymphedema engine looks healthier than it did three months ago, and the guidance raise on EBITDA suggests management sees margin follow-through in the fourth quarter. However, this quarter's beat was thin and came with a revenue miss and lower earnings. A third consecutive airway clearance cut, combined with explicitly measured 2027 commentary, leaves the stock without a clean growth catalyst until the product pipeline matures. The burden now shifts to the fourth quarter, which must show that the inventory overhang has bottomed and that rising spending can finally translate into operating leverage.